vTv Therapeutics (NASDAQ:VTVT) – Research analysts at Piper Jaffray decreased their FY2019 earnings per share (EPS) estimates for vTv Therapeutics in a research report issued on Tuesday, April 10th. Piper Jaffray analyst C. Duncan now forecasts that the biotechnology company will post earnings per share of ($2.84) for the year, down from their previous forecast of $0.93. Piper Jaffray currently has a “Neutral” rating and a $4.00 price target on the stock.
VTVT has been the subject of a number of other reports. Northland Securities downgraded vTv Therapeutics from an “outperform” rating to a “market perform” rating and set a $28.00 price objective for the company. in a report on Tuesday. Roth Capital downgraded vTv Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $18.00 to $17.00 in a report on Tuesday. Seaport Global Securities initiated coverage on vTv Therapeutics in a report on Thursday, March 29th. They set a “buy” rating and a $14.00 price objective for the company. Zacks Investment Research downgraded vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Finally, Canaccord Genuity set a $15.00 price objective on vTv Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $13.69.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.03). The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.10 million.
Several large investors have recently bought and sold shares of VTVT. Creative Planning bought a new position in shares of vTv Therapeutics during the fourth quarter worth about $114,000. Millennium Management LLC bought a new position in shares of vTv Therapeutics during the fourth quarter worth about $377,000. JPMorgan Chase & Co. bought a new position in shares of vTv Therapeutics during the third quarter worth about $481,000. State Street Corp grew its stake in vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Royce & Associates LP bought a new position in vTv Therapeutics in the fourth quarter valued at approximately $1,352,000. Institutional investors and hedge funds own 11.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “FY2019 EPS Estimates for vTv Therapeutics (VTVT) Cut by Analyst” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/13/fy2019-eps-estimates-for-vtv-therapeutics-vtvt-cut-by-analyst.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.